Hims & Hers Health (HIMS) 10-Q 9 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 06, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity Registrant Name	HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38986
Entity Tax Identification Number	98-1482650
Entity Address, Address Line One	2269 Chestnut Street, #523
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94123
City Area Code	415
Local Phone Number	851-0195
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	HIMS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001773751
Current Fiscal Year End Date	--12-31
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		197,685,152
Common Class V
Document Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		8,377,623

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 48,284	$ 71,784
Short-term investments	154,769	175,490
Inventory	12,143	13,558
Prepaid expenses and other current assets	16,750	9,073
Total current assets	231,946	269,905
Restricted cash	856	856
Goodwill	110,881	110,881
Intangibles, net	24,848	25,890
Operating lease right-of-use assets	4,787	5,111
Other long-term assets	8,721	7,942
Total assets	382,039	420,585
Current liabilities:
Accounts payable	23,906	19,640
Accrued liabilities	9,089	12,194
Deferred revenue	1,145	3,188
Earn-out payable	12,972	42,834
Operating lease liabilities	1,388	1,365
Total current liabilities	48,500	79,221
Operating lease liabilities	3,763	4,117
Earn-out liabilities	1,544	1,999
Other long-term liabilities	517	629
Total liabilities	54,324	85,966
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 197,503,386 and 196,414,363 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2022 and December 31, 2021	21	20
Additional paid-in capital	623,220	613,687
Accumulated other comprehensive loss	(323)	(137)
Accumulated deficit	(295,203)	(278,951)
Total stockholders' equity	327,715	334,619
Total liabilities and stockholders' equity	$ 382,039	$ 420,585

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common Class A
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	2,750,000,000	2,750,000,000
Common stock, shares issued (in shares)	197,503,386	196,414,363
Common stock, shares outstanding (in shares)	197,503,386	196,414,363
Common Class V
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, shares issued (in shares)	8,377,623	8,377,623
Common stock, shares outstanding (in shares)	8,377,623	8,377,623

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 101,314	$ 52,314
Cost of revenue	26,558	12,067
Gross profit	74,756	40,247
Operating expenses:
Marketing	48,093	26,958
Selling, general, and administrative	43,582	61,698
Total operating expenses	91,675	88,656
Loss from operations	(16,919)	(48,409)
Other income (expense):
Change in fair value of liabilities	441	(2,681)
Other income, net	320	(224)
Total other income (expense), net	761	(2,905)
Loss before income taxes	(16,158)	(51,314)
Provision for income taxes	(94)	(90)
Net loss	(16,252)	(51,404)
Other comprehensive loss	(186)	(61)
Total comprehensive loss	$ (16,438)	$ (51,465)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.08)	$ (0.34)
Diluted (in dollars per share)	$ (0.08)	$ (0.34)
Weighted average shares outstanding:
Basic (in shares)	202,695,970	153,080,538
Diluted (in shares)	202,695,970	153,080,538

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Redeemable Convertible Preferred Stock
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2020						93,328,118
Mezzanine equity, beginning balance at Dec. 31, 2020						$ 249,962
Increase (Decrease) in Temporary Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)						(206,511)
Pre-closing stock repurchase, net of exercise of vested options						$ (125)
Conversion of redeemable convertible preferred stock to common stock (in shares)						(93,121,607)
Conversion of redeemable convertible preferred stock to common stock						$ (249,837)
Mezzanine equity, ending balance (in shares) at Mar. 31, 2021						0
Mezzanine equity, ending balance at Mar. 31, 2021						$ 0
Beginning balance (in shares) at Dec. 31, 2020		52,967,106
Beginning balance at Dec. 31, 2020	$ (146,874)	$ 5	$ 24,424	$ (11)	$ (171,292)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Pre-closing stock repurchase, net of exercise of vested options (in shares)		(1,817,519)
Pre-closing stock repurchase, net of exercise of vested options	(21,902)		(21,902)
Conversion of redeemable convertible preferred stock to common stock (in shares)		93,121,607
Conversion of redeemable convertible preferred stock to common stock	249,837	$ 9	249,828
Repayment of related-party promissory notes associated with vested shares	854		854
Forfeiture of related-party promissory notes (in shares)		(370,734)
Conversion of Series D preferred stock warrants to Class A common warrants	1,160		1,160
Exercise of Class A common stock warrants (in shares)		1,867,292
Exercise of Class A common stock warrants	21,678		21,678
Issuance of common stock upon Merger, net of transaction costs of $16.2 million (in shares)		23,892,244
Issuance of common stock upon Merger, net of transaction costs of $16.2 million	129,659	$ 2	129,657
Issuance of PIPE shares (in shares)		7,500,000
Issuance of PIPE shares	75,000	$ 1	74,999
Issuance of earn-out shares to common stockholders (in shares)		14,153,520
Issuance of earn-out shares to common stockholders	1	$ 1
Exercise of vested stock options (in shares)		37,887
Exercise of vested stock options	80		80
Vesting of early exercised stock options	54		54
Warrant expense in connection with Merger	154		154
Stock-based compensation	34,230		34,230
Other comprehensive income	(61)			(61)
Net loss	(51,404)				(51,404)
Ending balance (in shares) at Mar. 31, 2021		191,351,403
Ending balance at Mar. 31, 2021	292,466	$ 18	515,216	(72)	(222,696)
Mezzanine equity, beginning balance (in shares) at Dec. 31, 2021						0
Mezzanine equity, beginning balance at Dec. 31, 2021						$ 0
Mezzanine equity, ending balance (in shares) at Mar. 31, 2022						0
Mezzanine equity, ending balance at Mar. 31, 2022						$ 0
Beginning balance (in shares) at Dec. 31, 2021		204,791,986
Beginning balance at Dec. 31, 2021	334,619	$ 20	613,687	(137)	(278,951)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes (in shares)		320,296
Payments for taxes related to net share settlement of equity awards	(404)		(404)
Exercise of vested stock options (in shares)		768,727
Exercise of vested stock options	891	$ 1	890
Vesting of early exercised stock options	38		38
Stock-based compensation	9,009		9,009
Other comprehensive income	(186)			(186)
Net loss	(16,252)				(16,252)
Ending balance (in shares) at Mar. 31, 2022		205,881,009
Ending balance at Mar. 31, 2022	$ 327,715	$ 21	$ 623,220	$ (323)	$ (295,203)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 16.2

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (16,252)	$ (51,404)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,741	394
Stock-based compensation	8,856	34,230
Change in fair value of liabilities	(441)	2,681
Warrant expense in connection with Merger	0	154
Amortization of debt issuance costs	0	144
Net amortization on securities	971	287
Benefit for deferred taxes	(112)	0
Non-cash operating lease cost	377	378
Non-cash other	(94)	165
Changes in operating assets and liabilities:
Inventory	1,415	(980)
Prepaid expenses and other current assets	(7,677)	(7,147)
Other long-term assets	(30)	(58)
Accounts payable	4,266	5,117
Accrued liabilities	(3,148)	1,114
Deferred revenue	(2,043)	(648)
Operating lease liabilities	(384)	(375)
Earn-out payable	(6,848)	0
Net cash used in operating activities	(19,403)	(15,948)
Investing activities
Purchases of investments	(84,881)	(172,021)
Maturities of investments	82,340	9,500
Proceeds from sales of investments	22,291	0
Investment in website development and internal-use software	(1,197)	(740)
Purchases of property, equipment, and intangible assets	(100)	(63)
Net cash provided by (used in) investing activities	18,453	(163,324)
Financing activities
Pre-closing stock repurchase	0	(22,027)
Proceeds from issuance of common stock upon Merger	0	197,686
Proceeds from PIPE	0	75,000
Payments for transaction costs related to securities issuances	0	(12,794)
Proceeds from repayment of promissory notes associated with vested and unvested shares	0	1,193
Proceeds from exercise of Class A common stock warrants	0	807
Proceeds from exercise of vested and unvested stock options	891	80
Payments for taxes related to net share settlement of equity awards	(404)	0
Payments for earn-out consideration for acquisitions	(23,014)	0
Net cash (used in) provided by financing activities	(22,527)	239,945
Foreign currency effect on cash and cash equivalents	(23)	2
(Decrease) increase in cash, cash equivalents, and restricted cash	(23,500)	60,675
Cash, cash equivalents, and restricted cash at beginning of period	72,640	28,350
Cash, cash equivalents, and restricted cash at end of period	49,140	89,025
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	48,284	88,169
Restricted cash	856	856
Total cash, cash equivalents, and restricted cash	49,140	89,025
Supplemental disclosures of cash flow information
Cash paid for taxes	36	59
Non-cash investing and financing activities
Recapitalization from redeemable convertible preferred stock pre-closing stock repurchase	0	125
Conversion of redeemable convertible preferred stock to common stock	0	249,837
Assumption of Merger warrants liability	0	51,814
Exercise of Private Placement Warrants and Public Warrants	0	20,871
Conversion of Series D preferred stock warrants to Class A common warrants	0	1,160
Vesting of early exercised stock options	$ 38	$ 54

Organization

Organization	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Hims & Hers Health, Inc. (the “Company” or “Hims & Hers”), formerly known as Oaktree Acquisition Corp. (“OAC”), incorporated in Delaware, is a multi-specialty telehealth platform transforming the way healthcare is delivered. The Company’s mission is to make healthcare accessible, affordable, and convenient for everyone. The Company’s digital platform enables access to treatments for a broad range of conditions, including those related to sexual health, hair loss, dermatology, mental health and primary care. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies on a subscription basis, making accessing treatments simple, affordable, and straightforward. Through the Hims & Hers mobile application, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. The Company offers a range of health and wellness products and services available for purchase directly by customers on the Company’s websites and mobile application. Additionally, Hims & Hers products can be found in tens of thousands of top retail locations in the United States. On January 20, 2021 (the “Closing Date”), OAC completed the acquisition of Hims, Inc. (“Hims”) pursuant to the Agreement and Plan of Merger dated as of September 30, 2020 (the “Merger Agreement”) by and among OAC, Hims, and Rx Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of OAC (“Merger Sub”). The Merger Agreement provided for, among other things, the combination of Hims and OAC pursuant to the merger of Merger Sub with and into Hims, with Hims continuing as the surviving entity and as a wholly-owned subsidiary of OAC, which changed its name to Hims & Hers Health, Inc. (the “Merger”). The Merger was accounted for as a reverse recapitalization with Hims as the accounting acquirer and OAC as the acquired company for accounting purposes.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of March 31, 2022 are unaudited. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the periods presented, but are not necessarily indicative of the results expected for the full fiscal year or any other period. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements. There have been no changes to the Company’s significant accounting policies described in the audited consolidated financial statements for the year ended December 31, 2021 that have had a material impact on these condensed consolidated financial statements and related notes. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, and estimates in capitalization of website development and internal-use software costs. Management believes that the estimates and judgments upon which it relies are reasonable based upon information available to it at the time that these estimates and judgments were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s condensed consolidated financial statements will be affected. Business Combinations The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. Goodwill of $110.9 million was acquired during the second and third quarters of 2021 and no goodwill impairment was recorded for the three months ended March 31, 2022. Impairment of Long-Lived Assets Long-lived assets include property and equipment and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of March 31, 2022 and December 31, 2021, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets. Revenue Recognition The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile application, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. Revenue consists of the following (in thousands): Three Months Ended March 31, 2022 2021 Online Revenue $ 94,102 $ 50,680 Wholesale Revenue 7,212 1,634 Total Revenue $ 101,314 $ 52,314 For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile application. For Wholesale Revenue, the Company defines its customer as a wholesale partner. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically within one day. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the three months ended March 31, 2022 and 2021, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 9 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites and mobile application for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with certain affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites and mobile application. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its websites and mobile application for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following month. For wholesale arrangements, payments are collected in accordance with contract terms.

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Short-term investments as of March 31, 2022, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 136,337 $ (129) $ 136,208 Government bonds 4,977 (14) 4,963 Asset-backed bonds 13,667 (69) 13,598 Total short-term investments $ 154,981 $ (212) $ 154,769 Short-term investments as of December 31, 2021, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 146,032 $ (30) $ 146,002 Asset-backed bonds 29,507 (19) 29,488 Total short-term investments $ 175,539 $ (49) $ 175,490

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following (in thousands): March 31, 2022 December 31, 2021 Finished goods $ 7,883 $ 10,428 Raw materials 4,260 3,130 Total inventory $ 12,143 $ 13,558

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, 2022 December 31, 2021 Wholesale trade receivables $ 5,463 $ 3,577 Prepaid expenses 10,051 4,606 Other current assets 1,236 890 Total prepaid expenses and other current assets $ 16,750 $ 9,073

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of March 31, 2022 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,939) $ 22,231 9.0 Other 3,846 (1,229) 2,617 2.2 Intangible assets, net $ 28,016 $ (3,168) $ 24,848 8.3 Intangible assets as of December 31, 2021 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,298) $ 22,872 9.2 Other 3,846 (828) 3,018 2.4 Intangible assets, net $ 28,016 $ (2,126) $ 25,890 8.4 Amortization expense for intangible assets was $1.0 million and less than $0.1 million for the three months ended March 31, 2022 and 2021, respectively. Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to March 31, 2022 is as follows (in thousands): The remainder of 2022 $ 3,124 2023 3,542 2024 2,801 2025 2,672 2026 2,455 2027 and thereafter 10,254 $ 24,848

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, 2022 December 31, 2021 Payroll costs $ 2,686 $ 3,363 Marketing expenses 2,322 3,158 Tax payables 1,007 954 Professional services 812 734 Product and shipping costs 761 2,635 Other accrued liabilities 1,501 1,350 Total accrued liabilities $ 9,089 $ 12,194

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Operating Leases	Operating Leases In January 2020, the Company entered into a 63-month non-cancelable lease for 302,880 square feet of warehouse space in New Albany, Ohio. The lease commenced on June 1, 2020. Total minimum lease payments are $7.9 million, net of rent abatement for an initial three-month period and with an annual escalation of 2.5%. The Company has the option to extend the lease term for a period of five years. The Company utilizes the reasonably certain threshold criteria in determining which options it will exercise. In January 2022, the Company entered into a 62 -month non-cancelable lease for 24,465 square feet of warehouse, distribution, and pharmacy space in Gilbert, Arizona. The lease commenced on May 1, 2022. Total minimum lease payments are $1.5 million , net of rent abatement for an initial two-month period and with annual escalation of 3.0% . The Company has the option to extend the lease term for a period of five years. The Company had not been given access to the facility as of March 31, 2022, and as a result there are no new lease liabilities during the quarter. For each of the three months ended March 31, 2022 and 2021, the Company recorded operating lease costs of $0.4 million, including variable operating lease costs of $0.1 million. Supplemental information related to the Company’s non-cancelable operating leases was as follows for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Operating cash flows used for operating lease $ 384 $ 375 Operating lease liability arising from adoption of ASC 842 $ — $ 6,756 Weighted average remaining lease term 3.4 years 4.4 years Weighted average discount rate 4.0% 4.0% Future minimum lease payments under the Company's non-cancelable operating leases with an initial lease term in excess of one year subsequent to March 31, 2022 are as follows (in thousands): The remainder of 2022 $ 1,175 2023 1,598 2024 1,638 2025 1,114 Gross lease payments 5,525 Less: imputed interest (374) Present value of net future minimum lease payments $ 5,151

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities The variable interest entities (“VIEs”) are: (i) professional corporations or other professional entities owned by licensed healthcare providers that engage licensed clinical professionals to provide consultation services (i.e., the “Affiliated Medical Groups”); and (ii) XeCare, LLC (“XeCare”) and Apostrophe Pharmacy LLC (“Apostrophe Pharmacy”, and together with XeCare, the “Affiliated Pharmacies”), each of which is a licensed mail order pharmacy providing prescription fulfillment services solely to the Company’s customers. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s condensed consolidated financial statements. As of March 31, 2022 and December 31, 2021, the Company’s condensed consolidated balance sheets included current and total assets of $2.9 million and $2.2 million, respectively, for the VIEs. As of March 31, 2022 and December 31, 2021, current and total liabilities were $2.2 million and $3.0 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases. The results of operations and cash flows of the VIEs are included in the Company’s condensed consolidated financial statements. For the three months ended March 31, 2022 and 2021, the VIEs charged the Company $12.2 million and $3.4 million, respectively, for services rendered. For the three months ended March 31, 2022 and 2021, operations of the VIEs generated net income and a net loss of $1.2 million and $1.8 million, respectively, inclusive of administrative expenses.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 35,464 $ — $ — $ 35,464 Government bonds — 6,533 — 6,533 Short-term investments: Corporate bonds — 136,208 — 136,208 Government bonds — 4,963 — 4,963 Asset-backed bonds — 13,598 — 13,598 Restricted cash: Money market funds 856 — — 856 Total assets $ 36,320 $ 161,302 $ — $ 197,622 Liabilities Earn-out liabilities $ — $ — $ 1,544 $ 1,544 Total liabilities $ — $ — $ 1,544 $ 1,544 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 59,761 $ — $ — $ 59,761 Government bonds — 7,664 — 7,664 Short-term investments: Corporate bonds — 146,002 — 146,002 Asset-backed bonds — 29,488 — 29,488 Restricted cash: Money market funds 856 — — 856 Total assets $ 60,617 $ 183,154 $ — $ 243,771 Liabilities Earn-out liabilities $ — $ — $ 1,999 $ 1,999 Total liabilities $ — $ — $ 1,999 $ 1,999 The fair values of cash, accounts receivable, accounts payable, accrued liabilities, and earn-out payable approximated their carrying values as of March 31, 2022 and December 31, 2021, due to their short-term nature. All other financial instruments except for earn-out liabilities are valued either based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. During the three months ended March 31, 2022 and 2021, the Company had no transfers between levels of the fair value hierarchy of its assets or liabilities measured at fair value. At inception, the fair value of the earn-out liabilities associated with the acquisition of Honest Health Limited, which is now Hims & Hers UK Limited (“HHL”), was determined based on revenue projections and probability of achievement of revenue targets as evaluated using a Monte Carlo simulation, which is considered a Level 3 fair value measurement containing significant unobservable inputs including estimates of achieving the revenue targets. The undiscounted range of contingent purchase consideration is nil to $3.3 million. The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 % The long-term earn-out liability, which is solely related to the HHL acquisition as of March 31, 2022 and December 31, 2021, remains classified as Level 3. The fair value of the earn-out liabilities is remeasured at each reporting period. This change in fair value is related to contingent consideration and compensation costs (see Note 12 – Stockholders’ Equity) and is recognized in other income (expense) and selling, general, and administrative expenses, respectively, on the condensed consolidated statements of operations and comprehensive loss. The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2021 $ 1,999 Change in fair value due to revaluation and service-based vesting (455) Balance at March 31, 2022 $ 1,544

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations The Company has contractual obligations to make future purchases, primarily related to cloud-based software contracts used in operations. As of March 31, 2022, purchase obligations were $2.3 million, with $1.2 million payable in 2022 and $1.1 million payable in 2023. Legal Proceedings

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stockholders’ Equity	Stockholders’ Equity Common Stock The Company has two classes of common stock, Class A and Class V common stock. The rights are identical, including liquidation and dividend rights, except Class V common stock has additional voting rights. RSU Releases During the three months ended March 31, 2022, the Company released 413,035 gross shares of Class A common stock upon vesting of restricted stock units (“RSUs”). In connection with the releases, 92,739 shares of Class A common stock were withheld for the payment of employee taxes. There were no RSU releases for the three months ended March 31, 2021. 2017 Stock Plan and 2020 Equity Incentive Plan In July 2017, Hims adopted the 2017 Stock Plan (the “2017 Plan”). Under the 2017 Plan, the board of directors of Hims granted awards, including incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSU awards, and other stock awards to employees, directors, and consultants of Hims. In January 2021, in connection with the Merger, the Board of Directors adopted the 2020 Equity Incentive Plan (the “2020 Plan”) and reserved 21,000,000 authorized shares of Class A common stock the Company could issue. In addition, up to 19,000,000 shares of Hims Class A common stock subject to awards granted under the 2017 Plan that were forfeited, expired, or lapsed unexercised or unsettled could be added to the 2020 Plan reserve. Beginning on January 1, 2022 and ending on January 1, 2031, the number of authorized shares of common stock under the 2020 Plan will automatically increase each fiscal year by 5% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year unless the Board of Directors approves a lesser number. As of the effective date of the 2020 Plan, no further stock awards have been or will be granted under the 2017 Plan. Through March 31, 2022, 1,766,696 shares of Class A common stock subject to awards granted under the 2017 Plan that were outstanding on the Closing Date and forfeited after the adoption of the 2020 Plan were added to the 2020 Plan reserve. Additionally, on January 1, 2022, 10,239,599 shares of Class A common stock were automatically added to the 2020 Plan reserve. Therefore, as of March 31, 2022, there were 33,006,295 shares of Class A common stock reserved and 17,102,197 shares of Class A common stock available for grant under the 2020 Stock Plan; there were no more shares available for grant under the 2017 Plan since the 2017 Plan was replaced by the 2020 Plan. 2020 Employee Stock Purchase Plan In January 2021, the Board of Directors adopted the Company’s Employee Stock Purchase Plan (“ESPP”), which became effective immediately prior to the Closing Date. The total shares of Class A common stock initially reserved under the ESPP is limited to 4,000,000 shares of Class A common stock. Beginning on January 1, 2022 and ending on January 1, 2041, the number of authorized shares of common stock under the ESPP will automatically increase each fiscal year by the lesser of (i) 1% of the total number of Class A and Class V common stock issued and outstanding on the last day of the preceding fiscal year, (ii) 12,000,000 shares of Class A common stock, or (iii) a number of shares of Class A common stock determined by the Board of Directors. On January 1, 2022, 2,047,919 shares of Class A common stock were automatically added to the ESPP reserve. Therefore, as of March 31, 2022, there were 6,047,919 shares of Class A common stock reserved and available for grant under the ESPP. Under the ESPP, eligible employees may purchase the Company’s Class A common stock during pre-specified offering periods at a discount established by the Company’s compensation committee. The purchase price is 85% of the lower of the fair market value of the Company’s Class A common stock on the first trading day of the offering period or the fair market value on the purchase date. Under the ESPP, the Company may specify offering periods with durations of not more than 27 months, and may specify shorter purchase periods within each offering period. Employees participating in the ESPP commence payroll withholdings that accumulate through the end of the respective offering period. As of March 31, 2022, $0.8 million has been withheld via employee payroll deductions for employees who have opted to participate in the purchase period ending May 2022. Stock Options Options for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date and then 1/48th of the total grant vesting monthly thereafter. Options granted to current employees generally vest 1/48th of the total grant monthly over four years. Options granted are exercisable within a period not exceeding ten years from the grant date. On June 17, 2020, the board of directors of Hims granted 3,246,139 and 1,623,070 stock options to the Chief Executive Officer (“CEO”) with an exercise price of $2.43 to vest upon either (i) an acquisition of the Company with per share consideration equal to at least $22.99 and $38.31, respectively, or (ii) a per share price on a public stock exchange that is at least equal to $22.99 and $38.31, respectively. The CEO is required to be employed at the time the per share consideration/price is achieved in order to receive the awards, but the awards are not subject to any other service condition. The Company recognizes expense related to these awards based on the fair value and derived service period as measured using a Monte Carlo simulation model, but only upon achieving the requirements outlined in (i) and (ii) above. The grant date fair value was $16.6 million for these awards. The $22.99 per share price threshold related to awards for the 3,246,139 stock options was achieved in February 2021 subsequent to the Merger and, therefore, the Company recognized all $11.3 million of expense related to the grant during the three months ended March 31, 2021 due to achievement of the market condition. As of March 31, 2022, there was $2.8 million of remaining compensation expense to be recognized for the remaining 1,623,070 stock options over a period of 2.04 years. On February 24, 2022, the Board of Directors granted 2,085,640 stock options to the CEO with an exercise price of $5.01 that vest in four equal tranches. On each anniversary date after February 24, 2022, 25% of the shares subject to the options will vest provided that (i) the CEO is employed on the anniversary date and (ii) the closing price of the Company’s Class A common stock is more than $10 per share in 20 of the 30 trading days prior to the anniversary date. The award is not subject to any other service condition. Vesting is cumulative in subsequent years if the market condition was not previously met. The Company recognizes expense related to this award for each tranche individually based on the fair value and requisite service period, which is the greater of the derived service period and the explicit service period. The fair value and the derived service term of the market condition were both measured using a Monte Carlo simulation model. The total grant date fair value was $3.8 million for this award. The Company recognized $0.1 million of expense related to the grant during the three months ended March 31, 2022. As of March 31, 2022, there was $3.7 million of remaining compensation expense to be recognized over a period of 3.90 years. In connection with the Merger, each Hims option holder received an equivalent award at an exchange ratio of 0.4530 that vests in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions for the three months ended March 31, 2022: Expected term (in years) 6.02 Expected volatility 56.7 % Risk-free interest rate 1.9 % Expected dividend yield — % Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 10,401 $ 4.01 7.73 $ 37,868 Granted 5,585 5.01 Exercised (including early exercised options vested during the period) (793) 1.20 Forfeited and expired (334) 5.58 Outstanding at March 31, 2022 14,859 4.51 8.55 26,306 Exercisable as of March 31, 2022 8,066 3.10 7.52 24,213 The weighted average grant date fair value of options granted for the three months ended March 31, 2022 was $2.71 per share, and the intrinsic value of vested options exercised was $3.3 million. As of March 31, 2022, there was $30.1 million of unrecognized stock-based compensation related to unvested stock options, excluding the CEO stock options, which is expected to be recognized over a weighted average period of 3.27 years. The options outstanding and exercisable as of March 31, 2022 (excluding the CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life Shares Weighted Average Remaining Contractual Life $ 0.06 – 0.40 1,912 5.92 1,912 5.92 1.55 – 1.75 1,829 7.13 1,737 7.13 2.43 2,946 8.18 2,946 8.18 5.01 5,585 9.91 95 9.91 8.13 – 9.41 1,634 8.88 1,199 8.72 12.21 – 15.17 953 8.91 177 8.17 14,859 8,066 RSUs All RSUs granted prior to the Merger were subject to achievement of a liquidity event which included (i) an initial public offering, (ii) a business combination transaction, or (iii) a sale event as defined by the 2017 Plan. On January 20, 2021, the liquidity event was achieved with the closing of the Merger. RSUs for new employees generally vest over four years, with 25% vesting one year after the vesting commencement date on the first Company Quarterly Vesting Date (defined below) and the remaining grant vesting quarterly thereafter on the specified vesting dates of March 15, June 15, September 15, and December 15 (each, a “Company Quarterly Vesting Date” or collectively, “Company Quarterly Vesting Dates”). Additional RSUs granted to current employees generally vest quarterly on Company Quarterly Vesting Dates over four years. In connection with the Merger, each Hims RSU holder received an equivalent award at an exchange ratio of 0.4530 that vests in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. In addition, all Hims RSU and option holders received (i) earn-out RSUs that would vest in equal thirds if the trading price of the Company’s Class A common stock was greater than or equal to $15.00, $17.50, and $20.00 for any 10 trading days within any 20-trading day period, or a Company sale (as defined in the Merger Agreement) occurs and the thresholds are met on or prior to the date that is five years following the Closing Date; and (ii) an allocation of approximately 35,000 RSUs (“Parent Warrant RSUs”). All of these RSUs vest in accordance with the terms of the initial RSU and option award, in addition to any of the aforementioned requirements. The earn-out thresholds for earn-out RSUs were all met in February 2021. RSU activity including RSUs outstanding prior to the Merger, earn-out RSUs, and Parent Warrant RSUs is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2021 3,982 11.55 Granted 3,863 5.01 Vested (373) 11.92 Forfeited and expired (172) 11.37 Unvested at March 31, 2022 7,300 $ 8.15 Included in the above activity are 476,308 earn-out RSUs and 9,478 Parent Warrant RSUs issued to the CEO as part of the Merger that vest in accordance with the same market conditions as the CEO stock options granted on June 17, 2020, of which 317,539 earn-out RSUs and 6,319 Parent Warrant RSUs have vested as of March 31, 2022. In addition, the Company granted 45,297 RSUs in 2020 and 4,431 earn-out RSUs and 88 Parent Warrant RSUs as part of the Merger in January 2021 to a non-executive officer that vest upon meeting certain revenue targets from the sale of specific products. None of the awards vested in the period. These grants are also included in the above activity. As of March 31, 2022, there was unrecognized stock-based compensation related to unvested RSUs of $46.3 million, which is expected to be recognized over a weighted average period of 3.27 years. Vendor Warrants As of March 31, 2022, there were 462,335 Class A common stock warrants issued to nonemployees in connection with vendor service arrangements outstanding and exercisable, with a weighted average exercise price of $1.75, a weighted average contractual term of 7.01 years, and an aggregate intrinsic value of $1.7 million. Upon the exercise of outstanding warrants, vendors also have the right to receive 45,225 shares of Merger consideration, consisting of the holders’ allocation of earn-out consideration. As of March 31, 2022, all stock-based compensation expense related to vendor warrants and associated earn-out shares has been recognized. Stock Subject to Vesting and Earn-out Share Liability In June 2021, the Company granted 447,553 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $5.5 million in connection with the acquisition of HHL. As part of the acquisition of HHL, the Company also recognized an earn-out liability based on the achievement of certain revenue targets. A portion of the earn-out liability is expected to be settled in shares of Class A common stock. Vesting of the restricted shares and a portion of total earn-out payable to specific individuals are contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the three months ended March 31, 2022. The expense will be recognized over a four-year vesting period with 25% vesting one year after the acquisition date and the remaining vesting quarterly thereafter. Unrecognized stock-based compensation expense of $4.6 million will be recognized over a weighted average period of 3.12 years. In July 2021, the Company granted 2,332,557 restricted shares of Class A common stock subject to vesting with an aggregate grant date fair value of $24.2 million in connection with the acquisition of YoDerm, Inc. (“Apostrophe”). Vesting of the restricted shares is contingent on each recipient’s continued employment. Accordingly, the Company has recognized stock-based compensation expense related to these awards for the three months ended March 31, 2022. The expense will be recognized over a three-year vesting period with 17% vesting 6 months after the acquisition date and the remaining vesting quarterly thereafter. Unrecognized stock-based compensation expense of $18.2 million will be recognized over a weighted average period of 2.25 years. Stock-Based Compensation Expense The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Marketing $ 823 $ 1,846 Selling, general, and administrative 8,033 32,384 Total stock-based compensation expense $ 8,856 $ 34,230 The Company capitalized $0.2 million of stock-based compensation as internal-use software for the three months ended March 31, 2022. The Company did not capitalize any stock-based compensation as internal-use software for the three months ended March 31, 2021.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Atomic Labs, LLC (“Atomic Labs”) is a related-party venture capital startup studio that launched the Company, providing initial capital and governance. The Company utilized operational support from Atomic Labs, primarily consisting of providing office space, conducting back-office professional services, and administering operating expenses. Additionally, an affiliated company of Atomic Labs provides professional services to the Company, primarily to support engineering and operations functions. All services were provided at cost. For the three months ended March 31, 2022 and 2021, the Company recorded a total of $0.9 million and $0.8 million, respectively, for payments made to an affiliated company of Atomic Labs for services performed and costs incurred on behalf of the Company. In addition, for the three months ended March 31, 2022 and 2021, the Company recorded $0.2 million and $0.1 million, respectively, for payments made to Vouched, a related-party company that provides identity verification services.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid for the three months ended March 31, 2022 and 2021. Undistributed earnings for each period are allocated equally to participating securities based on the contractual participation rights of the security to share in the current earnings as if all current period earnings had been distributed. The Company’s basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average shares of common stock outstanding during periods with undistributed losses. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31 (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Class A Class V Class A Class V Numerator: Net loss attributable to common stockholders $ (15,580) $ (672) $ (49,185) $ (2,219) Denominator: Weighted average shares outstanding, basic and diluted 194,318,347 8,377,623 146,471,524 6,609,014 Basic and diluted net loss per share $ (0.08) $ (0.08) $ (0.34) $ (0.34) Basic net loss per share is the same as diluted net loss per share attributable to common stockholders for the three months ended March 31, 2022 and 2021, because the inclusion of potential shares of common stock would have been anti-dilutive for the periods presented. The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Stock options 17,685,246 16,361,955 RSUs 5,366,963 3,347,300 Common stock issued subject to vesting 2,395,670 — Warrants to purchase Class A common stock 561,058 7,733,346 Common stock issuable under the ESPP 444,828 — Common stock issued for early exercise of stock options 103,521 388,839 Redeemable convertible preferred stock — 19,702,603 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 3,545,821

Income Tax

Income Tax	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax	Income TaxThe effective income tax rate was (0.6)% and (0.2)% for the three months ended March 31, 2022 and 2021. The effective tax rate differs from the U.S. federal rate primarily due to the impacts of the valuation allowance placed on the Company’s deferred tax assets and state taxes.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements as of March 31, 2022 are unaudited. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended December 31, 2021 (the “audited consolidated financial statements”). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s balance sheet, results of operations, and cash flows for the periods presented, but are not necessarily indicative of the results expected for the full fiscal year or any other period.
Consolidation	The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany transactions and balances have been eliminated in these condensed consolidated financial statements. There have been no changes to the Company’s significant accounting policies described in the audited consolidated financial statements for the year ended December 31, 2021 that have had a material impact on these condensed consolidated financial statements and related notes.
Use of Estimates	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The more significant estimates and assumptions by management include, among others, valuation of inventory, valuation and recognition of stock-based compensation expense, valuation of contingent consideration in business combinations, purchase price allocation for business combinations, and estimates in capitalization of website development and internal-use software costs. Management believes that the estimates and judgments upon which it relies are reasonable based upon information available to it at the time that these estimates and judgments were made. Actual results experienced by the Company may differ from management’s estimates. To the extent that there are material differences between these estimates and actual results, the Company’s condensed consolidated financial statements will be affected.
Business Combinations	The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of acquisition. When the Company issues stock-based or cash awards to an acquired company’s shareholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain assumed obligations.
Goodwill	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually in the fourth quarter or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company operates as one reporting unit. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill.
Impairment of Long-Lived Assets	Long-lived assets include property and equipment and intangible assets subject to amortization. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In such cases, recoverability of assets to be held and used is assessed by comparing the carrying amount of assets with their future underlying net undiscounted cash flows without interest charges. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of March 31, 2022 and December 31, 2021, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets.
Revenue Recognition	The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.The Company’s consolidated revenue primarily comprises online sales of health and wellness products and services through the Company’s websites and mobile application, including prescription and non-prescription products. In contracts that contain prescription products issued as the result of a consultation, revenue also includes medical consultation services provided by Affiliated Medical Groups (defined below). Additionally, the Company offers a range of health and wellness products through wholesale partners. For Online Revenue, the Company defines its customer as an individual who purchases products or services through its websites or mobile application. For Wholesale Revenue, the Company defines its customer as a wholesale partner. The transaction price in the Company’s contracts with customers is the total amount of consideration to which the Company expects to be entitled in exchange for transferring products or services to the customer. The Company’s contracts that contain prescription products issued as the result of a consultation include two performance obligations: access to (i) products and (ii) consultation services. The Company’s contracts for prescription refills and contracts that do not contain prescription products have a single performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company satisfies its performance obligation for services over the period of the consultation service, which is typically within one day. The customer obtains control of the products and services upon the Company’s completion of its performance obligations. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis. The stand-alone selling price is based on the prices at which the Company separately sells the products and services, as well as market and cost plus estimates. For each of the three months ended March 31, 2022 and 2021, service revenue represented less than 10% of consolidated revenues. To fulfill its promise to customers for contracts that include professional medical consultations, the Company maintains relationships with various “Affiliated Medical Groups,” which are professional corporations or other professional entities owned by licensed physicians and that engage licensed healthcare professionals (physicians, physician assistants, nurse practitioners, and mental health providers; collectively referred to as “Providers” or individually, a “Provider”) to provide consultation services. Refer to Note 9 – Variable Interest Entities. The Company accounts for service revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company determines which Affiliated Medical Group and Provider provides the consultation to the customer; (ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its sole discretion, sets all listed prices charged on its websites and mobile application for products and services. Additionally, to fulfill its promise to customers for contracts that include sale of prescription products, the Company maintains relationships with certain affiliated and third-party pharmacies (“Partner Pharmacies” or individually, a “Partner Pharmacy”) to fill prescriptions that are ordered by the Company’s customers for fulfillment through the Company’s websites and mobile application. The Company accounts for prescription product revenue as a principal in the arrangement with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Partner Pharmacy fills a customer’s prescription; (ii) Partner Pharmacies fill the prescription based on fulfillment instructions provided by the Company, including using the Company’s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) the Company, at its sole discretion, sets all listed prices charged on its websites and mobile application for products and services. The Company estimates refunds using the expected value method based on historical refunds granted to customers. The Company updates its estimate at the end of each reporting period and recognizes the estimated amount as contra-revenue with a corresponding refund liability. Sales, value-added, and other taxes are excluded from the transaction price and, therefore, from revenue. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been transferred to the customer, in cost of revenue. For online sales, payment for prescription medication and non-prescription products is typically collected from the customer a few days in advance of product shipment. Contract liabilities are recorded when payments have been received from the customer for undelivered products or services and are recognized as revenue when the performance obligations are later satisfied. Contract liabilities consisting of balances related to customer prepayments are recognized as current deferred revenue on the condensed consolidated balance sheets since the associated revenue will be primarily recognized within the following month. For wholesale arrangements, payments are collected in accordance with contract terms.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenue consists of the following (in thousands): Three Months Ended March 31, 2022 2021 Online Revenue $ 94,102 $ 50,680 Wholesale Revenue 7,212 1,634 Total Revenue $ 101,314 $ 52,314

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Short-term investments as of March 31, 2022, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 136,337 $ (129) $ 136,208 Government bonds 4,977 (14) 4,963 Asset-backed bonds 13,667 (69) 13,598 Total short-term investments $ 154,981 $ (212) $ 154,769 Short-term investments as of December 31, 2021, consist of the following (in thousands): Adjusted Unrealized Fair Corporate bonds $ 146,032 $ (30) $ 146,002 Asset-backed bonds 29,507 (19) 29,488 Total short-term investments $ 175,539 $ (49) $ 175,490

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventory consists of the following (in thousands): March 31, 2022 December 31, 2021 Finished goods $ 7,883 $ 10,428 Raw materials 4,260 3,130 Total inventory $ 12,143 $ 13,558

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, 2022 December 31, 2021 Wholesale trade receivables $ 5,463 $ 3,577 Prepaid expenses 10,051 4,606 Other current assets 1,236 890 Total prepaid expenses and other current assets $ 16,750 $ 9,073

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets as of March 31, 2022 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,939) $ 22,231 9.0 Other 3,846 (1,229) 2,617 2.2 Intangible assets, net $ 28,016 $ (3,168) $ 24,848 8.3 Intangible assets as of December 31, 2021 consist of the following (in thousands): Gross Accumulated Net Weighted Trade name $ 24,170 $ (1,298) $ 22,872 9.2 Other 3,846 (828) 3,018 2.4 Intangible assets, net $ 28,016 $ (2,126) $ 25,890 8.4
Finite-lived Intangible Assets Amortization Expense	Amortization that will be charged to expense over the remaining life of the intangible assets subsequent to March 31, 2022 is as follows (in thousands): The remainder of 2022 $ 3,124 2023 3,542 2024 2,801 2025 2,672 2026 2,455 2027 and thereafter 10,254 $ 24,848

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): March 31, 2022 December 31, 2021 Payroll costs $ 2,686 $ 3,363 Marketing expenses 2,322 3,158 Tax payables 1,007 954 Professional services 812 734 Product and shipping costs 761 2,635 Other accrued liabilities 1,501 1,350 Total accrued liabilities $ 9,089 $ 12,194

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lease, Supplemental Information	Supplemental information related to the Company’s non-cancelable operating leases was as follows for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Operating cash flows used for operating lease $ 384 $ 375 Operating lease liability arising from adoption of ASC 842 $ — $ 6,756 Weighted average remaining lease term 3.4 years 4.4 years Weighted average discount rate 4.0% 4.0%
Lessee, Operating Lease, Liability, Maturity	Future minimum lease payments under the Company's non-cancelable operating leases with an initial lease term in excess of one year subsequent to March 31, 2022 are as follows (in thousands): The remainder of 2022 $ 1,175 2023 1,598 2024 1,638 2025 1,114 Gross lease payments 5,525 Less: imputed interest (374) Present value of net future minimum lease payments $ 5,151

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 35,464 $ — $ — $ 35,464 Government bonds — 6,533 — 6,533 Short-term investments: Corporate bonds — 136,208 — 136,208 Government bonds — 4,963 — 4,963 Asset-backed bonds — 13,598 — 13,598 Restricted cash: Money market funds 856 — — 856 Total assets $ 36,320 $ 161,302 $ — $ 197,622 Liabilities Earn-out liabilities $ — $ — $ 1,544 $ 1,544 Total liabilities $ — $ — $ 1,544 $ 1,544 The Company’s fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021, is as follows (in thousands): Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents: Money market funds $ 59,761 $ — $ — $ 59,761 Government bonds — 7,664 — 7,664 Short-term investments: Corporate bonds — 146,002 — 146,002 Asset-backed bonds — 29,488 — 29,488 Restricted cash: Money market funds 856 — — 856 Total assets $ 60,617 $ 183,154 $ — $ 243,771 Liabilities Earn-out liabilities $ — $ — $ 1,999 $ 1,999 Total liabilities $ — $ — $ 1,999 $ 1,999
Fair Value Measurement Inputs and Valuation Techniques	The following assumptions were used to determine the fair value at inception: HHL Revenue risk-adjusted discount rate 9.1 % Revenue volatility 50.0 % Counterparty discount rate 5.0 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The change in the fair value of earn-out liabilities is as follows (in thousands): Balance at December 31, 2021 $ 1,999 Change in fair value due to revaluation and service-based vesting (455) Balance at March 31, 2022 $ 1,544

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions for the three months ended March 31, 2022: Expected term (in years) 6.02 Expected volatility 56.7 % Risk-free interest rate 1.9 % Expected dividend yield — %
Share-based Payment Arrangement, Option, Activity	Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years): Shares Weighted Weighted Aggregate Outstanding at December 31, 2021 10,401 $ 4.01 7.73 $ 37,868 Granted 5,585 5.01 Exercised (including early exercised options vested during the period) (793) 1.20 Forfeited and expired (334) 5.58 Outstanding at March 31, 2022 14,859 4.51 8.55 26,306 Exercisable as of March 31, 2022 8,066 3.10 7.52 24,213
Share-based Payment Arrangement, Option, Exercise Price Range	The options outstanding and exercisable as of March 31, 2022 (excluding the CEO stock options) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price): Options Outstanding Options Exercisable Exercise Price Shares Weighted Average Remaining Contractual Life Shares Weighted Average Remaining Contractual Life $ 0.06 – 0.40 1,912 5.92 1,912 5.92 1.55 – 1.75 1,829 7.13 1,737 7.13 2.43 2,946 8.18 2,946 8.18 5.01 5,585 9.91 95 9.91 8.13 – 9.41 1,634 8.88 1,199 8.72 12.21 – 15.17 953 8.91 177 8.17 14,859 8,066
Share-based Payment Arrangement, Restricted Stock Unit, Activity	RSU activity including RSUs outstanding prior to the Merger, earn-out RSUs, and Parent Warrant RSUs is as follows (in thousands, except for weighted average grant date fair value): Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2021 3,982 11.55 Granted 3,863 5.01 Vested (373) 11.92 Forfeited and expired (172) 11.37 Unvested at March 31, 2022 7,300 $ 8.15
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, 2022 2021 Marketing $ 823 $ 1,846 Selling, general, and administrative 8,033 32,384 Total stock-based compensation expense $ 8,856 $ 34,230

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31 (in thousands, except share and per share amounts): Three Months Ended March 31, 2022 2021 Class A Class V Class A Class V Numerator: Net loss attributable to common stockholders $ (15,580) $ (672) $ (49,185) $ (2,219) Denominator: Weighted average shares outstanding, basic and diluted 194,318,347 8,377,623 146,471,524 6,609,014 Basic and diluted net loss per share $ (0.08) $ (0.08) $ (0.34) $ (0.34)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table discloses weighted-average securities that were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Stock options 17,685,246 16,361,955 RSUs 5,366,963 3,347,300 Common stock issued subject to vesting 2,395,670 — Warrants to purchase Class A common stock 561,058 7,733,346 Common stock issuable under the ESPP 444,828 — Common stock issued for early exercise of stock options 103,521 388,839 Redeemable convertible preferred stock — 19,702,603 Common stock issued for exercise of stock options subject to nonrecourse promissory notes — 3,545,821

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended	6 Months Ended
	Mar. 31, 2022USD ($)reportingUnit	Sep. 30, 2021USD ($)
Accounting Policies [Abstract]
Number of reporting unit | reportingUnit	1
Goodwill, acquired during period		$ 110,900,000
Goodwill, impairment loss	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total Revenue	$ 101,314	$ 52,314
Online Revenue
Disaggregation of Revenue [Line Items]
Total Revenue	94,102	50,680
Wholesale Revenue
Disaggregation of Revenue [Line Items]
Total Revenue	$ 7,212	$ 1,634

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Adjusted Cost	$ 154,981	$ 175,539
Unrealized Losses	(212)	(49)
Fair Value	154,769	175,490
Corporate bonds
Marketable Securities [Line Items]
Adjusted Cost	136,337	146,032
Unrealized Losses	(129)	(30)
Fair Value	136,208	146,002
Government bonds
Marketable Securities [Line Items]
Adjusted Cost	4,977
Unrealized Losses	(14)
Fair Value	4,963
Asset-backed bonds
Marketable Securities [Line Items]
Adjusted Cost	13,667	29,507
Unrealized Losses	(69)	(19)
Fair Value	$ 13,598	$ 29,488

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 7,883	$ 10,428
Raw materials	4,260	3,130
Total inventory	$ 12,143	$ 13,558

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Wholesale trade receivables	$ 5,463	$ 3,577
Prepaid expenses	10,051	4,606
Other current assets	1,236	890
Total prepaid expenses and other current assets	$ 16,750	$ 9,073

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 28,016	$ 28,016
Accumulated Amortization	(3,168)	(2,126)
Net Carrying Value	$ 24,848	$ 25,890
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	8 years 3 months 18 days	8 years 4 months 24 days
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 24,170	$ 24,170
Accumulated Amortization	(1,939)	(1,298)
Net Carrying Value	$ 22,231	$ 22,872
Trade name | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	9 years	9 years 2 months 12 days
Other
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 3,846	$ 3,846
Accumulated Amortization	(1,229)	(828)
Net Carrying Value	$ 2,617	$ 3,018
Other | Weighted Average
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	2 years 2 months 12 days	2 years 4 months 24 days

Intangible Assets - Amortizatio

Intangible Assets - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to intangible assets	$ 1,000	$ 100
The remainder of 2022	3,124
2023	3,542
2024	2,801
2025	2,672
2026	2,455
2027 and thereafter	10,254
Net Carrying Value	$ 24,848		$ 25,890

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]
Payroll costs	$ 2,686	$ 3,363
Marketing expenses	2,322	3,158
Tax payables	1,007	954
Professional services	812	734
Product and shipping costs	761	2,635
Other accrued liabilities	1,501	1,350
Total accrued liabilities	$ 9,089	$ 12,194

Operating Leases - Additional D

Operating Leases - Additional Details (Details) $ in Thousands	1 Months Ended		3 Months Ended
	Jan. 31, 2022USD ($)ft²	Jan. 31, 2020USD ($)ft²	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
Minimum lease payments			$ 5,525
Operating lease costs			400	$ 400
Variable lease costs			100	$ 100
Operating leases, future minimum payments due			5,151
Operating leases, current, future minimum payments due			1,388		$ 1,365
Operating leases, noncurrent, future minimum payments due			$ 3,763		$ 4,117
New Albany, Ohio
Lessee, Lease, Description [Line Items]
Operating lease, term of contract		63 months
Area of real estate property | ft²		302,880
Minimum lease payments		$ 7,900
Lessee, operating lease, rent abatement period		3 months
Rent expense, annual escalation, percent		2.50%
Operating lease, renewal term		5 years
Gilbert, Arizona
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	62 months
Area of real estate property | ft²	24,465
Minimum lease payments	$ 1,500
Lessee, operating lease, rent abatement period	2 months
Rent expense, annual escalation, percent	3.00%
Operating lease, renewal term	5 years

Operating Leases - Lease Costs

Operating Leases - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating cash flows used for operating lease	$ 384	$ 375
Operating lease liability arising from adoption of ASC 842	$ 0	$ 6,756
Weighted average remaining lease term	3 years 4 months 24 days	4 years 4 months 24 days
Weighted average discount rate	4.00%	4.00%

Operating Leases - Lease Liabil

Operating Leases - Lease Liability (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
The remainder of 2022	$ 1,175
2023	1,598
2024	1,638
2025	1,114
Gross lease payments	5,525
Less: imputed interest	(374)
Present value of net future minimum lease payments	$ 5,151

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Variable Interest Entity [Line Items]
Current assets	$ 231,946		$ 269,905
Assets	382,039		420,585
Current liabilities	48,500		79,221
Liabilities	54,324		85,966
Net income (loss)	(16,252)	$ (51,404)
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Current assets	2,900		2,900
Assets	2,200		2,200
Current liabilities	2,200		2,200
Liabilities	3,000		$ 3,000
Payments for services	12,200	3,400
Net income (loss)	$ 1,200	$ (1,800)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 197,622	$ 243,771
Earn-out liabilities	1,544	1,999
Total liabilities	1,544	1,999
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	136,208	146,002
Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	4,963
Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	13,598	29,488
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	35,464	59,761
Restricted cash	856	856
Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	6,533	7,664
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	36,320	60,617
Earn-out liabilities	0	0
Total liabilities	0	0
Level 1 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 1 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Level 1 | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	35,464	59,761
Restricted cash	856	856
Level 1 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	161,302	183,154
Earn-out liabilities	0	0
Total liabilities	0	0
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	136,208	146,002
Level 2 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	4,963
Level 2 | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	13,598	29,488
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Level 2 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	6,533	7,664
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Earn-out liabilities	1,544	1,999
Total liabilities	1,544	1,999
Level 3 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0
Level 3 | Asset-backed bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Level 3 | Government bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Honest Health Limited	Jun. 11, 2021USD ($)
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability	$ 0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business combination, contingent consideration, liability	$ 3,300,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assumptions (Details) - Level 3 - Valuation, Income Approach - Honest Health Limited	Mar. 31, 2022
Revenue risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.091
Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.500
Counterparty discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out liability, measurement input	0.050

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of Earn-out Liabilities (Details) - Earn-out Liability $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2021	$ 1,999
Change in fair value due to revaluation and service-based vesting	(455)
Balance at March 31, 2022	$ 1,544

Commitments and Contingencies -

Commitments and Contingencies - Additional Details (Details) $ in Millions	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 2.3
Purchase obligation, to be paid, remainder of fiscal year	1.2
Purchase obligation, to be paid, year one	$ 1.1

Stockholders_ Equity - Common S

Stockholders’ Equity - Common Stock and RSU Releases (Details)	3 Months Ended
	Mar. 31, 2022commonStockClassshares	Mar. 31, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of classes of common stock | commonStockClass	2
RSUs | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, restricted stock award, gross (in shares)	413,035	0
Share-based payment arrangement, shares withheld for tax withholding obligation (in shares)	92,739

Stockholders_ Equity - 2017 Sto

Stockholders’ Equity - 2017 Stock Plan and 2020 Equity Incentive Plan (Details) - USD ($) $ in Millions	Jan. 01, 2022	Jan. 31, 2021	Mar. 31, 2022
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding and issued stock		1.00%
Employee-related Liabilities			$ 0.8
Employee Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock plan offering period		27 months
Employee Stock | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		4,000,000	6,047,919
Number of shares added to plan reserve (in shares)	2,047,919
Number of shares available for grant (in shares)			6,047,919
Shares (in shares)		12,000,000
Purchase price of common stock, percent		85.00%
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		21,000,000	33,006,295
Percentage increase in authorized shares of common stock		5.00%
Number of shares added to plan reserve (in shares)	10,239,599
Number of shares available for grant (in shares)			17,102,197
2017 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)		19,000,000
Number of authorized shares transferred between plans, cumulative (in shares)			1,766,696
Number of shares available for grant (in shares)			0

Stockholders_ Equity - Stock Op

Stockholders’ Equity - Stock Options Narrative (Details) $ / shares in Units, $ in Thousands	Feb. 24, 2022USD ($)d$ / sharesshares	Jun. 17, 2020USD ($)$ / sharesshares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)	Feb. 28, 2021shares	Jan. 20, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense			$ 8,856	$ 34,230
Recapitalization exchange ratio						0.4530
Weighted average grant date fair value (in dollars per share) | $ / shares			$ 2.71
Intrinsic value of exercises during period			$ 3,300
Chief Executive Officer | June 17, 2020 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 2,800
Options outstanding (in shares) | shares			1,623,070
Chief Executive Officer | June 17, 2020 Grant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares		3,246,139
Awards granted (in dollars per share) | $ / shares		$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares		$ 22.99
Grant date fair value		$ 16,600
Exercisable at the end of the period (in shares) | shares					3,246,139
Chief Executive Officer | June 17, 2020 Grant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares		1,623,070
Awards granted (in dollars per share) | $ / shares		$ 2.43
Acquisition with shares consideration threshold (in dollars per share) | $ / shares		$ 38.31
Chief Executive Officer | February 24, 2022 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award granted (in shares) | shares	2,085,640
Awards granted (in dollars per share) | $ / shares	$ 5.01
Grant date fair value	$ 3,800
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 3,700
Share-based payment arrangement, option, share price trigger (in dollars per share) | $ / shares	$ 10
Share-based payment arrangement, option, threshold trading days | d	20
Share-based payment arrangement, option, threshold consecutive trading days | d	30
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payments arrangement, nonvested award, option, cost not yet recognized, amount			$ 30,100
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)			10 years
Stock options | Chief Executive Officer | June 17, 2020 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense				$ 11,300
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 14 days
Stock options | Chief Executive Officer | February 24, 2022 Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vesting rights, percentage	25.00%
Total stock-based compensation expense			$ 100
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 10 months 24 days
Stock options | New Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Award vesting rights, monthly percentage			2.083%
Stock options | New Employee | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Awards vesting rights, percentage			25.00%
Stock options | Current Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Award vesting rights, monthly percentage			2.083%
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 3 months 7 days

Stockholders_ Equity - Weighted

Stockholders’ Equity - Weighted Average Fair Value Assumptions (Details) - Stock options	3 Months Ended
	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 7 days
Expected volatility	56.70%
Risk-free interest rate	1.90%
Expected dividend yield	0.00%

Stockholders_ Equity - Option A

Stockholders’ Equity - Option Activity (Details) - Employee, excluding CEO - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Shares
Beginning balance (in shares)	10,401
Granted (in shares)	5,585
Exercised (including early exercised options vested during the period) (in shares)	(793)
Forfeited and expired (in shares)	(334)
Ending balance (in shares)	14,859	10,401
Exercisable at the end of the period (in shares)	8,066
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 4.01
Granted (in dollars per share)	5.01
Exercised (including early exercised options vested during the period) (in dollars per share)	1.20
Forfeited and expired (in dollars per share)	5.58
Ending balance (in dollars per share)	4.51	$ 4.01
Exercisable at the end of the period (in dollars per share)	$ 3.10
Weighted Average Contractual Period (in Years)
Outstanding balance (in years)	8 years 6 months 18 days	7 years 8 months 23 days
Exercisable at the end of the period (in years)	7 years 6 months 7 days
Aggregate Intrinsic Value
Outstanding balance	$ 26,306	$ 37,868
Exercisable at the end of the period	$ 24,213

Stockholders_ Equity - Exercise

Stockholders’ Equity - Exercise Price Range of Options Outstanding and Exercisable (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Options Outstanding
Shares (in shares)	14,859
Options Exercisable
Shares (in shares)	8,066
Exercise Price Range $0.06 to $0.40
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 0.06
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 0.40
Options Outstanding
Shares (in shares)	1,912
Weighted Average Remaining Contractual Life  (in Years)	5 years 11 months 1 day
Options Exercisable
Shares (in shares)	1,912
Weighted Average Remaining Contractual Life  (in Years)	5 years 11 months 1 day
Exercise Price Range $1.55 to $1.75
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 1.55
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 1.75
Options Outstanding
Shares (in shares)	1,829
Weighted Average Remaining Contractual Life  (in Years)	7 years 1 month 17 days
Options Exercisable
Shares (in shares)	1,737
Weighted Average Remaining Contractual Life  (in Years)	7 years 1 month 17 days
Exercise Price Range $2.43
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 2.43
Options Outstanding
Shares (in shares)	2,946
Weighted Average Remaining Contractual Life  (in Years)	8 years 2 months 4 days
Options Exercisable
Shares (in shares)	2,946
Weighted Average Remaining Contractual Life  (in Years)	8 years 2 months 4 days
Exercise Price Range $5.01
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 5.01
Options Outstanding
Shares (in shares)	5,585
Weighted Average Remaining Contractual Life  (in Years)	9 years 10 months 28 days
Options Exercisable
Shares (in shares)	95
Weighted Average Remaining Contractual Life  (in Years)	9 years 10 months 28 days
Exercise Price Range $8.13 to $9.41
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 8.13
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 9.41
Options Outstanding
Shares (in shares)	1,634
Weighted Average Remaining Contractual Life  (in Years)	8 years 10 months 17 days
Options Exercisable
Shares (in shares)	1,199
Weighted Average Remaining Contractual Life  (in Years)	8 years 8 months 19 days
Exercise Price Range $12.21 to $15.17
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based payments arrangement, option, exercise price range, lower range limit (in dollars per share) | $ / shares	$ 12.21
Share-based payments arrangement, option, exercise price range, upper range limit (in dollars per share) | $ / shares	$ 15.17
Options Outstanding
Shares (in shares)	953
Weighted Average Remaining Contractual Life  (in Years)	8 years 10 months 28 days
Options Exercisable
Shares (in shares)	177
Weighted Average Remaining Contractual Life  (in Years)	8 years 2 months 1 day

Stockholders_ Equity - RSUs Nar

Stockholders’ Equity - RSUs Narrative (Details) $ / shares in Units, $ in Millions	Jan. 20, 2021day$ / sharesshares	Jan. 31, 2021shares	Mar. 31, 2022USD ($)shares	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recapitalization exchange ratio	0.4530
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger one (in dollars per share) | $ / shares	$ 15
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger two (in dollars per share) | $ / shares	17.50
Reverse recapitalization, contingent consideration, equity, earnout period, stock price trigger three (in dollars per share) | $ / shares	$ 20
Reverse recapitalization, contingent consideration, equity, earnout period, threshold trading days | day	10
Reverse recapitalization, contingent consideration, equity, earnout period, threshold consecutive trading days | day	20
Reverse recapitalization, contingent consideration, equity, earnout period	5 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			4 years
Granted (in shares)			3,863,000	45,297
Vested (in shares)			373,000
Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $			$ 46.3
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 3 months 7 days
RSUs | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			1 year
Awards vesting rights, percentage			25.00%
Earn Out Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares)			317,539
Earn Out Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			476,308
Earn Out Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		4,431
Parent Warrant Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, outstanding (in shares)	35,000
Vested (in shares)			6,319
Parent Warrant Restricted Stock Units | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			9,478
Parent Warrant Restricted Stock Units | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		88

Stockholders_ Equity - RSUs Act

Stockholders’ Equity - RSUs Activity (Details) - RSUs - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2020
Shares
Beginning balance (in shares)	3,982,000
Granted (in shares)	3,863,000	45,297
Vested (in shares)	(373,000)
Forfeited and expired (in shares)	(172,000)
Ending balance (in shares)	7,300,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 11.55
Granted (in dollars per share)	5.01
Vested (in dollars per share)	11.92
Forfeited and expired (in dollars per share)	11.37
Ending balance (in dollars per share)	$ 8.15

Stockholders_ Equity - Vendor W

Stockholders’ Equity - Vendor Warrants Narrative (Details) - Vendor Warrants $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuded (in shares)	462,335
Outstanding (in shares)	462,335
Exercisable (in shares)	462,335
Exercisable and outstanding (in dollars per share) | $ / shares	$ 1.75
Exercisable and outstanding (in years)	7 years 3 days
Exercisable and outstanding, intrinsic value | $	$ 1.7
Earn-Out Consideration
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number securities called by warrants or rights (in shares)	45,225

Stockholders_ Equity - Stock Su

Stockholders’ Equity - Stock Subject to Vesting and Earn-out Share Liability (Details) - Restricted Stock - USD ($) $ in Millions	Jun. 11, 2021	Jul. 31, 2021	Mar. 31, 2022
Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 4.6
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			3 years 1 month 13 days
Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount			$ 18.2
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition			2 years 3 months
Employee | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Employee | Honest Health Limited | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	447,553
Aggregate grant date fair value	$ 5.5
Employee | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		3 years
Employee | Apostrophe | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		2,332,557
Aggregate grant date fair value		$ 24.2
Employee | Share-based Payment Arrangement, Tranche One | Honest Health Limited
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	1 year
Awards vesting rights, percentage	25.00%
Employee | Share-based Payment Arrangement, Tranche One | Apostrophe
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)		6 months
Awards vesting rights, percentage		17.00%

Stockholders_ Equity - Summary

Stockholders’ Equity - Summary of Stock-Based Compensation Expense for Employees and Nonemployees (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 8,856,000	$ 34,230,000
Share-based payment arrangement, amount capitalized	200,000	0
Marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	823,000	1,846,000
Selling, general, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 8,033,000	$ 32,384,000

Related-Party Transactions (Det

Related-Party Transactions (Details) - Affiliated Entity - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 0.9	$ 0.8
Identity Verification Services
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 0.2	$ 0.1

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Share - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Dividends, common stock	$ 0	$ 0

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to common stockholders	$ (16,252)	$ (51,404)
Denominator:
Weighted average shares outstanding, basic (in shares)	202,695,970	153,080,538
Weighted average shares outstanding, diluted (in shares)	202,695,970	153,080,538
Basic net loss per share (in dollars per share)	$ (0.08)	$ (0.34)
Diluted net loss per share (in dollars per share)	$ (0.08)	$ (0.34)
Common Class A
Numerator:
Net loss attributable to common stockholders	$ (15,580)	$ (49,185)
Denominator:
Weighted average shares outstanding, basic (in shares)	194,318,347	146,471,524
Weighted average shares outstanding, diluted (in shares)	194,318,347	146,471,524
Basic net loss per share (in dollars per share)	$ (0.08)	$ (0.34)
Diluted net loss per share (in dollars per share)	$ (0.08)	$ (0.34)
Common Class V
Numerator:
Net loss attributable to common stockholders	$ (672)	$ (2,219)
Denominator:
Weighted average shares outstanding, basic (in shares)	8,377,623	6,609,014
Weighted average shares outstanding, diluted (in shares)	8,377,623	6,609,014
Basic net loss per share (in dollars per share)	$ (0.08)	$ (0.34)
Diluted net loss per share (in dollars per share)	$ (0.08)	$ (0.34)

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Share - Schedule of Excluded Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	17,685,246	16,361,955
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,366,963	3,347,300
Common stock issued subject to vesting
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,395,670	0
Warrants to purchase Class A common stock | Common Class A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	561,058	7,733,346
Common stock issuable under the ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	444,828	0
Common stock issued for early exercise of stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	103,521	388,839
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	19,702,603
Common stock issued for exercise of stock options subject to nonrecourse promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	3,545,821

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Effective income tax rate reconciliation, percent	(0.60%)	(0.20%)